Pembrolizumab (anti-PD-1)

Cat. No.: HY-P9902A Purity: 99.90%: FAQs
Data Sheet SDS COA

Molarity Calculator

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.

For research use only. We do not sell to patients.

Pembrolizumab (anti-PD-1) Chemical Structure

Size	Price	Stock	Quantity
1 mg	USD 230	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 720	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

2 Publications Citing Use of MCE Pembrolizumab (anti-PD-1)

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1^[1]^[2].
In Vitro	Deferoxamine (Df) chelates pembrolizumab and does not block or alter the binding affinity or specificity of pembrolizumab to CD4+ and CD8+ T cells^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Pembrolizumab (anti-PD-1) Related Antibodies
In Vivo	Experiments confirmed that ⁸⁹Zr-Df-Pembrolizumab has a specific activity of 740 mBq/mg antibody. mBq is the unit of radioactivity, used to measure radioactive decay^[2]. Positron emitter ⁸⁹Zr-labeled deferoxamine (Df)-Pembrolizumab, through PET imaging, its biodistribution has be dynamically tracked. The results shows that pembrolizumab remained stable in the blood circulation and accumulated most in liver and spleen tissues. And it shows similar biodistribution and pharmacokinetics in mice and rat^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance	Liquid
Color	Colorless to light yellow
SMILES	[Pembrolizumab (anti-PD-1)]
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Purity: 99.90% Select Batch: Data Sheet (260 KB) SDS (251 KB) COA (231 KB) Handling Instructions (2659 KB)
References	[1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X. [Content Brief] [2]. England CG, et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58(1):162-168. [Content Brief]